Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p

The usage of doxorubicin is hampered by its life-threatening cardiotoxicity in clinical practice. Dexrazoxane is the only cardioprotective medicine approved by the FDA for preventing doxorubicin-induced cardiac toxicity. Nevertheless, the mechanism of dexrazoxane is incompletely understood. The aim...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Biomed Res Int
Главные авторы: Yu, Xiaoxue, Ruan, Yang, Shen, Tao, Qiu, Quan, Yan, Mingjing, Sun, Shenghui, Dou, Lin, Huang, Xiuqing, Wang, Que, Zhang, Xiyue, Man, Yong, Tang, Weiqing, Jin, Zening, Li, Jian
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7071803/
https://ncbi.nlm.nih.gov/pubmed/32190669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/5107193
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы